

StemRIM Announces Publication of a Paper on a Physician-Initiated Phase 2 Clinical Trial of Redasemtide (HMGB1 Peptide) for Chronic Liver Disease

Osaka, Japan, May 14, 2026 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “StemRIM”) announces the publication of a paper on a physician-initiated Phase 2 clinical trial for Chronic Liver Disease (CLD) conducted on Redasemtide (HMGB1 peptide). Details are provided below.

Title : Safety and efficacy profile of S-005151 (Redasemtide), in patients with chronic liver diseases: phase 2 trial
Journal : Inflammation and Regeneration
Publication Date : May 2026
URL : <https://doi.org/10.1186/s41232-026-00421-9>

This paper reports that Redasemtide is well-tolerated in patients with CLD and may have therapeutic effects, in reducing liver damage and improving liver fibrosis.

Under our mission to "Overcoming Intractable diseases with "Regeneration-Inducing Medicine™", StemRIM remain committed to advancing "Regeneration-Inducing Medicine™" as innovative therapeutic solutions for patients suffering from intractable diseases.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit multipotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain

injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

X: [@StemRIM_Inc](#)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)